Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)
News | PET Imaging
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time November 02, 2022
arrow
Top trends boosting the industry expansion through 2028
Feature | Contrast Media | By Shankar Khatkale
Imaging Contrast Agents Global Market Outlook

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

Time November 02, 2022
arrow
The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
News | PET Imaging
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
Company announces SCINTIX as new product name for its flagship biology-guided radiotherapy technology
News | PET-CT
RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022

October 24, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 24, 2022
arrow
18F-SMBT-1 PET studies showed that beta-amyloid+ Alzheimer’s disease (AD) patients, but most importantly, beta-amyloid+ controls (CN) have significantly higher regional 18F-SMBT-1 binding than beta-amyloid- CN, with 18F-SMBT-1 retention highly associated with beta-amyloid burden. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of beta-amyloid accumulation.
News | PET Imaging
Novel PET Imaging Agent Detects Earliest Signs of Alzheimer's Disease

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18F-rhPSMA-7.3 clinical data and images.
News | PET Imaging
Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3

October 19, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2022
arrow
Based on Spectrum Dynamics digital SPECT/CT platform, VERITON-CT 400 Series provides the benefits of increased sensitivity and throughput to clinical applications based on high energy isotopes used in Nuclear Medicine
News | SPECT-CT
World's First Digital SPECT/CT Capable of High Energy Imaging Enables Full Range of Clinical Capabilities to Nuclear Medicine Centers

October 18, 2022 — Spectrum Dynamics announced its newest development in digital nuclear medicine imaging: the ...

Time October 18, 2022
arrow
Mirion Technologies, Inc., a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment.
News | Quality Assurance (QA)
Mirion Technologies Appoints Michael Rossi as President of Mirion Medical

October 7, 2022 — Mirion Technologies, Inc., a global provider of radiation detection, measurement, analysis and ...

Time October 07, 2022
arrow
The center will be equipped with a Cyclone KIUBE offering the highest production capacity with a PET cyclotron.
News | Radiopharmaceuticals and Tracers
ElsMed, Novatec and IBA Sign Contract to Install Radiopharmaceutical Production Center in Georgia

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
Free-breathing phase-resolved functional lung (PREFUL) low-field MRI at 0.55T with calculated parameters at an axial plane after automatic registration to a mid-expiration position and lung parenchyma segmentation. From left to right, representative color-coded images of functional show ventilation defects (VDP, blue), perfusion defects (QDP, red), ventilation/perfusion (V/Q match, green), ventilation/perfusion defects (V/Q defect, purple) in a healthy control (upper row, 7-year-old male), a participant rec
Feature | Radiology Business
Top 10: September's Most-read Content

Here is a recap of what ITN viewers found most interesting during the month of September: 1. Lasting Lung Damage Seen in ...

Time October 03, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

September 28, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 28, 2022
arrow
Ground-breaking research funded by National Cancer Institute
News | PET-CT
Xoran Partners With WVU to Develop PET/CT Scanner for Head and Neck Cancers (HNCs)

September 28, 2022 — Xoran Technologies is engaged in a ground-breaking research project to develop a PET/CT scanner for ...

Time September 28, 2022
arrow
IBA Rhodotron TT300-HE electron beam accelerator (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron Electron Beam Accelerators for Commercial Production of Radioisotopes

September 22, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 22, 2022
arrow
As the world, particularly the imaging community, is aware, disruptions in a pharmaceutical supply chain have impacted the global availability, and shortage of, iohexol iodinated contrast media (ICM), a common agent used in a multitude of CT and X-ray exams.
Feature | Contrast Media | By Christine Book
Contrast Media Supply Shortage: How and What Now?

The theme “Everyday progress” seems appropriate for the imaging community in 2022. What a year it’s been. Supply ...

Time September 14, 2022
arrow
For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative imaging and service solutions to healthcare facilities regardless of their size, location or capital budget. That vision is as strong today as it was back in 1980.
News | PET-CT
SMS first to bring Mobile Digital PET/CT to North Dakota and Montana

September 13, 2022 — For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative ...

Time September 13, 2022
arrow
Philips Spectral Angio CT suite
News | SPECT-CT
Philips Announces New Milestones in the Development of the World’s First Spectral Detector Angio CT Solution

September 12, 2022 — Royal Philips, a global leader in health technology, announced new milestones in the development of ...

Time September 12, 2022
arrow
Patients with detectable PSA (0.2-2.0 ng/mL) post-prostatectomy considered for salvage radiotherapy undergoing 18F-DCFPyl PSMA PET/CT staging. Image created by M.Ng et al, GenesisCare, Melbourne, Australia.
News | Prostate Cancer
New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50% of Prostate Cancer Patients

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
Societies Outline Recommendations for Hardware and Software, Training, Competency, Cross-specialty Collaboration, More
News | SPECT-CT
New ASNC-led Guideline Details How to Use CT in Hybrid Nuclear-CT Cardiac Imaging

September 7, 2022 — The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to ...

Time September 07, 2022
arrow
Accuray Will Anchor Hub That Will Unite Companies From the MedTech, Pharma and Biosciences Sectors, Physicians and Scientists
News | Radiology Business
Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster

September 7, 2022 — Accuray Incorporated announced the company is joining forces with Genolier Innovation Hub, a fully ...

Time September 07, 2022
arrow
Three machine deal expands potential of biology-guided radiotherapy to Pacific Northwest
News | PET Imaging
RefleXion Announces Multi System Contract with Select Healthcare

August 30, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT), a ...

Time August 30, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now